An observational study in Hypersomnia, sponsored by Centre d'Investigation Clinique et Technologique 805. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-26.
Sponsored by Centre d'Investigation Clinique et Technologique 805 · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Disorders of Excessive Somnolence with a site in France — 9 open to participants now, 10 under way, 4 of them phase 3. Disorders of Excessive Somnolence · France.
Among the 30 studies in Disorders of Excessive Somnolence with a site in France, this one is the only one that started in 2018, is one of 6 observational ones, and was the 15th registered.
196 studies on the registry are indexed under Disorders of Excessive Somnolence; 34 are open to participants now.
Browse Disorders of Excessive Somnolence studies →9 of the 30 studies in Disorders of Excessive Somnolence with a site in France are open now. Recruiting first, the newest first:
Alkermes, Inc. · Sites in France, United States, Australia and 7 more countries
Ages 18–70
Alkermes, Inc. · Sites in France, United States, Australia and 7 more countries
Ages 18–70
University Hospital, Bordeaux · Sites in France
Ages 18–65 · Healthy volunteers
Alkermes, Inc. · Sites in France, United States, Australia and 5 more countries
Ages 18–70
Hospices Civils de Lyon · Sites in France
Ages 18–65
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 30 Disorders of Excessive Somnolence studies recruiting now, 12 (40%) set no upper age limit and 17 (57%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 13
First in 2003; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is close to the median of 104 across 29 observational studies indexed under Disorders of Excessive Somnolence.
Median enrollment 130 across the 24 interventional studies, 110 across the 6 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 30 have an industry lead sponsor. The 10 most frequent:
Centre d'Investigation Clinique et Technologique 805 is the lead sponsor of 75 studies on the registry; 2 are open to participants now.
Centre d'Investigation Clinique et Technologique 805 has 1 study filed under Disorders of Excessive Somnolence — fewer than ten, so there is no comparison to draw.
7 of the studies in Disorders of Excessive Somnolence with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06366464Phase 3Harmony Biosciences Management, Inc.A Study of Pitolisant in Patients With Prader-Willi Syndrome | 2027-04 |
| NCT07502443Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | 2027-05 |
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
| NCT06457945Hospices Civils de LyonMind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions | 2026-12-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 30 studies in Disorders of Excessive Somnolence with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
7 to 14 days actimetry recording in order to exclude sleep deprivation just before hospitalisation for differential diagnosis of hypersomnia
This is an observational study
Urine drug screening will also be performe
The suty includes four centers in France
The study duration is of one year
patients with a sleepiness evoking a primary hypersomnia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
mean total sleep time
mean total sleep time as measured by actimetry durind the 7 - 14 days before hospitalisation
Time frame: 7-14 days before hospitalisation
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2018 to primary completion in Jan 2020, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Disorders of Excessive Somnolence →
Centre d'Investigation Clinique et Technologique 805